An observational study in Drug Use Disorder, Opioid Dependence and Opioid-Related Disorders, sponsored by Yale University. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Yale University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Opioid-Related Disorders by Yale University — 20 open to participants now, 24 under way, 1 of them phase 3. Opioid-Related Disorders · Yale University.
Among the 106 studies in Opioid-Related Disorders by Yale University, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 9 that started in 2024, is one of 11 observational ones, reaches primary completion later than 22 of the 23 other live ones, and was the 94th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →20 of the 106 studies in Opioid-Related Disorders by Yale University are open now, in 4 countries. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 25–65 · Healthy volunteers
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 26 · Phase 3 7 · Phase 4 9
First in 1988; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 129 across 184 observational studies indexed under Opioid-Related Disorders.
Median enrollment 62 across the 94 interventional studies, 108 across the 11 observational. Of the 75 that completed or were terminated, 27 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
10 of the studies in Opioid-Related Disorders by Yale University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06494904Phase 3Yale UniversityStandard Versus High Dose ED-Initiated Buprenorphine Induction | 2027-09 |
| NCT05333341Yale UniversityPain Care at Home to Amplify Function (Pain CHAMP) | 2026-11-30 |
| NCT01730781Yale UniversityImaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning | 2026-12 |
| NCT06160284Yale UniversityExploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) | 2027-01 |
| NCT06207162Yale UniversityLongitudinal Neural Fingerprinting of Opioid-use Trajectories | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 106 studies in Opioid-Related Disorders by Yale University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project examines functional connectivity patterns associated with subsequent relapse to illicit opioids during treatment for OUD.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
This study's planned enrollment of 240 is above the median of 129 across 184 observational studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Compared within Opioid-Related Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Substance-Related Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Participants will be individuals with primary opioid use disorder who are at least 18 years old and enrolled in formal MOUD treatment (either methadone or buprenorphine) for less than 6 months. Investigators will recruit a sample that is 50% female and 50% male.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants initiated into methadone within the past 6 months will receive fMRI and cognitive assessment battery.
Diagnostic Test: fMRI
Participants initiated into buprenorphine within the past 6 months will receive fMRI and cognitive assessment battery.
Diagnostic Test: fMRI
Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task, Drug cue task, and Cognitive behavioral therapy task. Participants are not presented with any specific stimulus.
Illicit opioid-use
Defined as the percent days of self-reported use of illicit opioids (assessed at monthly visits for 6-months following neuroimaging), with the exception of primary type of MOUD (i.e., methadone for methadone treated individuals, buprenorphine for buprenorphine treated individuals).
Time frame: At monthly visits for 6 months following neuroimaging
MOUD retention
Percentage of visits attended out of visits expected based on electronic health record data and time line follow back.
Time frame: up to 9 months
Plan to share: Yes — This study will submit and share data with OpenNeuro. This will include de-identified demographic data, neuropsychological assessment data, clinical assessment data, and fMRI data (raw).
Time frame: All data will be deposited to OpenNeuro starting 24 months after data collection begins and will be deposited every six months thereafter. OpenNeuro policy states that any data uploaded to their repository becomes publicly available under a Creative Commons CC0 license after a 36-month period beginning from first successful version of the dataset.
Access criteria: OpenNeuro policy states that any data uploaded to their repository becomes publicly available under a Creative Commons (CC) license after a 36-month period beginning from first successful version of the dataset. Users create an account with OpenNeuro account in order to download BIDS formatted files and any associated metadata.
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Nov 2029, 59 months after the start.
Of 74 non-industry observational studies under Opioid-Related Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 59 months is above that.
Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.